Relapsed/Refractory Mantle Cell Lymphoma: How Would You Care for These Virtual Patients?

A 78-year-old man with a history of MCL presents with increasing fatigue and worsening lymphadenopathy while on second-line targeted therapy. Which of the following tests must be performed to appropriately evaluate this patient?

A 67-year-old woman with MCL was treated with second-line acalabrutinib for 2 years. She developed increasing fatigue and worsening lymphadenopathy and was found to have progressive disease. Based on current guidelines and clinical data, which third-line therapy is most appropriate?

A 70-year-old man is diagnosed with R/R MCL approximately 5 years after first-line bendamustine/rituximab. He is getting ready to begin a BTK inhibitor as second-line therapy. As you discuss potential adverse events and strategies to prevent these events, which of the following is most commonly associated with BTK inhibitor therapies and should be included in the discussion?